The experimental group received 5 mg/kg morphine, the BPC-157 groups received 10, 20, or 40 g/kg BPC-157, and the control group received normal saline (all the same volume)
Shoulder range of motion is maybe 80% of what it should be versus 40% before
Serious risks include pancreatitis (stop medication and seek immediate medical attention for severe abdominal pain radiating to the back), gallbladder disease, acute kidney injury (typically secondary to dehydration from gastrointestinal symptoms), and hypersensitivity reactions
Possible Side Effects Mild injection site reaction (transient) Rare: temporary skin discoloration at injection site Very low systemic side effect profile No hormonal effects Important: GHK-Cu has an extensive safety record across decades of research in cosmetic and medical applications
Tesamorelin is FDA-approved under the brand name EGRIFTA SV for reducing excess visceral abdominal fat
For those with subclinical lows